← Leaderboards
D. Martin Watterson
Northwestern University
$26,546,028
Attributed
$38,271,819
Total exposure
12
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.6M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$38,271,819 · 12
By mechanism
U01$24,740,188 · 5
R01$7,946,868 · 4
R42$3,155,525 · 1
R44$1,657,173 · 1
T32$772,065 · 1
Top collaborators
- Linda J Van Eldik12 shared
- Ottavio Arancio5 shared
- Victor Shifrin2 shared
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposS DiseaseFunctional DisorderSynapsesDisease ProgressionSmall MoleculeBrainPharmaceutical PreparationsClinical TrialsAttenuatedFutureNeurogliaNeurodegenerative DisordersCytokineAnimal ModelBaseToxicologyCentral Nervous System DiseasesInvestigationProductionDrug DiscoveryPre-ClinicalFoundationsDrug Candidate
Grant awards (47)
GMP Production and Extended Toxicology of an Oral Formulation Drug for Alzheimer's Disease$815,581
U01 · FY2025 · AG · contact PI
GMP Production and Extended Toxicology of an Oral Formulation Drug for Alzheimer's Disease$1,546,636
U01 · FY2024 · AG · contact PI
GMP Production and Extended Toxicology of an Oral Formulation Drug for Alzheimer's Disease$1,370,663
U01 · FY2024 · AG · contact PI
GMP Production and Extended Toxicology of an Oral Formulation Drug for Alzheimer's Disease$1,547,324
U01 · FY2023 · AG · contact PI
Preclinical development of a novel small molecule inhibitor of Alzheimer's disease-related cognitive impairment$1,444,837
U01 · FY2023 · AG · contact PI
Preclinical development of a novel small molecule inhibitor of Alzheimer's disease-related cognitive impairment$329,000
U01 · FY2023 · AG · contact PI
GMP Production and Extended Toxicology of an Oral Formulation Drug for Alzheimer's Disease$1,546,977
U01 · FY2022 · AG · contact PI
Preclinical development of a novel small molecule inhibitor of Alzheimer's disease-related cognitive impairment$1,516,817
U01 · FY2022 · AG · contact PI
Preclinical development of a novel small molecule inhibitor of Alzheimer's disease-related cognitive impairment$1,472,881
U01 · FY2021 · AG · contact PI
First-in-human SAD & MAD trials for MW151, a novel Alzheimer's disease drug candidate that attenuates proinflammatory cytokine dysregulation$1,193,602
R01 · FY2021 · AG
First-in-human SAD & MAD trials for MW151, a novel Alzheimer's disease drug candidate that attenuates proinflammatory cytokine dysregulation$336,600
R01 · FY2021 · AG
First-in-human SAD & MAD trials for MW151, a novel Alzheimer's disease drug candidate that attenuates proinflammatory cytokine dysregulation$1,505,935
R01 · FY2020 · AG
Preclinical development of a novel small molecule inhibitor of Alzheimer's disease-related cognitive impairment$1,475,773
U01 · FY2020 · AG · contact PI
Production and quality analysis of clinical drug for a novel CNS protein kinase inhibitor therapeutic candidate$631,965
R42 · FY2020 · AG · contact PI
Production and quality analysis of clinical drug for a novel CNS protein kinase inhibitor therapeutic candidate$2,018,653
R42 · FY2019 · AG · contact PI
First-in-human SAD & MAD trials for MW151, a novel Alzheimer's disease drug candidate that attenuates proinflammatory cytokine dysregulation$1,403,277
R01 · FY2019 · AG
First-in-human study of MW151, a novel drug targeting neuroinflammation$1,157,853
R44 · FY2019 · AG
Production and quality analysis of clinical drug for a novel CNS protein kinase inhibitor therapeutic candidate$504,907
R42 · FY2018 · AG · contact PI
First-in-human study of MW151, a novel drug targeting neuroinflammation$499,320
R44 · FY2018 · AG
Preclinical Development of a Selective Suppressor of Neuroinflammation for MCI/AD$1,468,850
U01 · FY2017 · AG
Preclinical Development of a Selective Suppressor of Neuroinflammation for MCI/AD$1,403,404
U01 · FY2016 · AG
Preclinical Alzheimers Disease Drug Development of Novel MAPK Inhibitors$1,382,636
U01 · FY2016 · AG · contact PI
Preclinical Development of a Selective Suppressor of Neuroinflammation for MCI/AD$1,416,252
U01 · FY2015 · AG
Preclinical Alzheimers Disease Drug Development of Novel MAPK Inhibitors$1,339,269
U01 · FY2015 · AG · contact PI
Preclinical Alzheimers Disease Drug Development of Novel MAPK Inhibitors$499,989
U01 · FY2015 · AG · contact PI
Preclinical Alzheimers Disease Drug Development of Novel MAPK Inhibitors$1,141,669
U01 · FY2014 · AG · contact PI
Preclinical Alzheimers Disease Drug Development of Novel MAPK Inhibitors$902,779
U01 · FY2013 · AG · contact PI
Preclinical Alzheimers Disease Drug Development of Novel MAPK Inhibitors$958,225
U01 · FY2012 · AG · contact PI
Development of Novel p38 MAPK Inhibitors as Therapeutics for CNS Disorders$293,487
R01 · FY2012 · AG · contact PI
Development of Novel p38 MAPK Inhibitors as Therapeutics for CNS Disorders$293,487
R01 · FY2011 · AG · contact PI
Integrative Chemical Biology of Neurodegeneration: Foundation to Novel Therapies$258,965
R01 · FY2011 · NS · contact PI
Drug Discovery Training in Age-Related Disorders$389,940
T32 · FY2010 · AG · contact PI
Development of Novel p38 MAPK Inhibitors as Therapeutics for CNS Disorders$305,334
R01 · FY2010 · AG · contact PI
Integrative Chemical Biology of Neurodegeneration: Foundation to Novel Therapies$261,608
R01 · FY2010 · NS · contact PI
Drug Discovery Training in Age-Related Disorders$382,125
T32 · FY2009 · AG · contact PI
Development of Novel p38 MAPK Inhibitors as Therapeutics for CNS Disorders$308,418
R01 · FY2009 · AG · contact PI
Integrative Chemical Biology of Neurodegeneration: Foundation to Novel Therapies$264,250
R01 · FY2009 · NS · contact PI
Development of a Novel Anti-Neuroinflammatory AD Therapeutic$449,429
U01 · FY2008 · AG · contact PI
Development of Novel p38 MAPK Inhibitors as Therapeutics for CNS Disorders$308,418
R01 · FY2008 · AG · contact PI
Integrative Chemical Biology of Neurodegeneration: Foundation to Novel Therapies$264,250
R01 · FY2008 · NS · contact PI
Development of a Novel Anti-Neuroinflammatory AD Therapeutic$75,500
U01 · FY2008 · AG · contact PI
Development of a Novel Anti-Neuroinflammatory AD Therapeutic$316,771
U01 · FY2007 · AG · contact PI
Novel Anti-Neuroinflammatory AD Therapeutic$318,926
U01 · FY2006 · AG · contact PI
Discovery of a New Class of Neuroproductive Compounds$231,450
R01 · FY2006 · NS · contact PI
Discovery of a New Class of Neuroproductive Compounds$237,019
R01 · FY2005 · NS
Discovery of a New Class of Neuroproductive Compounds$240,384
R01 · FY2004 · NS
Discovery of a New Class of Neuroprotective Compounds$240,384
R01 · FY2003 · NS